Vir Biotechnology signs $65M upfront deal with Gilead for solid tumor T-cell engager

Vir Biotechnology announced a new collaboration with Gilead Sciences focused on a solid tumor T-cell engager.

Under the agreement, Gilead will provide an upfront payment of $65 million and up to $45 million in near-term milestone payments.

The partnership aims to advance the development of the T-cell engager, with both companies expecting to share development costs and potential future revenues.